Related Experiment Videos
Fetal cartilage engineering from amniotic mesenchymal progenitor cells
Shaun M Kunisaki1, Russell W Jennings, Dario O Fauza
1Advanced Fetal Care Center and the Department of Surgery, Children's Hospital Boston, MA 02115, USA.
Stem Cells and Development
|May 2, 2006
Summary
Mesenchymal amniocytes from amniotic fluid can be engineered into cartilage tissue. This cartilage engineering approach shows promise for treating congenital anomalies.
Area of Science:
- Regenerative Medicine
- Tissue Engineering
- Developmental Biology
Background:
- Mesenchymal progenitor cells (MPCs) are crucial for tissue regeneration.
- Amniotic fluid is a potential source of progenitor cells for therapeutic applications.
- Current methods for cartilage repair have limitations.
Purpose of the Study:
- To investigate the potential of mesenchymal amniocytes for cartilage engineering.
- To evaluate the chondrogenic differentiation capacity of cells from ovine amniotic fluid.
- To compare engineered cartilage with native fetal hyaline cartilage.
Main Methods:
- Isolation and immunocytochemical confirmation of mesenchymal amniocytes from ovine amniotic fluid.
- Culture of cells as micromass pellets and on polyglycolic acid scaffolds in chondrogenic medium with TGF-beta2 and IGF-1.
- Comparison with fetal dermal fibroblast pellets.
- Histological and quantitative analysis of engineered constructs and native cartilage.
Main Results:
- Mesenchymal amniocytes demonstrated positive staining for vimentin and cytokeratins, confirming their identity.
- Micromass pellets and scaffold-seeded constructs from mesenchymal amniocytes showed chondrogenic differentiation.
- Dermal fibroblast pellets did not replicate these chondrogenic findings.
- Engineered cartilage exhibited similar glycosaminoglycans and elastin content to native cartilage, but lower collagen type II.
Conclusions:
- Mesenchymal amniocytes are suitable for in vitro cartilage engineering.
- Cartilage derived from amniotic fluid offers a potential therapeutic strategy for congenital anomalies.
- Further research may optimize collagen type II production for enhanced cartilage regeneration.